Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 3,055 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cancer Colon Clear all
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

NCT05581004
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions
Enzelkitug, Atezolizumab, Pembrolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 29, 2026, 10:34 PM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

NCT00040599
View directory record Official record
Conditions
Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumor
Interventions
hMN14 (labetuzumab)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
5
States / cities
Newport Beach, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 29, 2026, 10:34 PM EDT
Recruiting No phase listed Observational

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

NCT06418204
View directory record Official record
Conditions
Breast Carcinoma, Colorectal Carcinoma, Lung Non-Small Cell Carcinoma, Melanoma, Non-Hodgkin Lymphoma
Interventions
Non-interventional Study
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
483
States / cities
Fairbanks, Alaska • Kingman, Arizona • Phoenix, Arizona + 376 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 29, 2026, 10:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors

NCT05572684
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
Interventions
NC410, pembrolizumab
Drug
Lead sponsor
NextCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
Tucson, Arizona • Aurora, Colorado • Edgewood, Kentucky + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 29, 2026, 10:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Safety,Usability and Compliance of Using C-Scan System for Providing Information on Colonic Polypoid Lesions and Masses

NCT03735407
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
C-Scan procedure
Device
Lead sponsor
Check-Cap Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 29, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

NCT03050814
View directory record Official record
Conditions
Colorectal Tumors, Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer
Interventions
Avelumab, Ad-CEA vaccine, Bevacizumab, 5-Fluorouracil (FU), Leucovorin, Oxaliplatin, Capecitabine
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 29, 2026, 10:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Traditional Print Communication Methods, Simple Electronic Communication Methods, or Usual Care in Increasing How Often Older Women Undergo Colorectal Cancer Screening

NCT00459030
View directory record Official record
Conditions
Colorectal Cancer
Interventions
educational intervention via internet, educational intervention mailed, No additional educational intervention
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
904 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 29, 2026, 10:34 PM EDT
Recruiting Not applicable Interventional

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT07059884
View directory record Official record
Conditions
Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma
Interventions
Exercise Intervention, Telemedicine, Aerobic Exercise Intervention, Accelerometry, Questionnaire Administration, Interview, Electronic Health Record Review
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Dublin, California • Fremont, California • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 29, 2026, 10:34 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation

NCT01547130
View directory record Official record
Conditions
Colonic Neoplasms
Interventions
Normal (0.9%) saline, HalfLytely
Drug
Lead sponsor
Arya, Vijaypal, M.D., P.C.
Individual
Eligibility
21 Years to 70 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Middle Village, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Oct 29, 2026, 10:34 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Garden-fresh Produce and Exercise Reduce Colon Cancer Risk

NCT03976284
View directory record Official record
Conditions
Garden-fresh Produce and Exercise (GFPE)
Interventions
Garden-fresh produce and exercise
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 29, 2026, 10:34 PM EDT
Completed Phase 3 Interventional Results available

Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer

NCT01345175
View directory record Official record
Conditions
Rectal Cancer
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
3
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 29, 2026, 10:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer

NCT02318901
View directory record Official record
Conditions
Advanced Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer
Interventions
Pembrolizumab, Trastuzumab, ado-trastuzumab emtansine, Cetuximab
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 29, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab

NCT00321100
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
bevacizumab, cetuximab, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 29, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

NCT01326000
View directory record Official record
Conditions
Colorectal Cancer
Interventions
FOLFIRI, RO5083945, cetuximab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Encinitas, California • Highland, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 29, 2026, 10:34 PM EDT
Completed No phase listed Observational

High Definition Single Cell Analysis in Colorectal Cancer

NCT02809716
View directory record Official record
Conditions
Metastatic Carcinoma in the Liver, Stage IV Colorectal Cancer
Interventions
Biomarker Analysis, Cytology Specimen Collection Procedure
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
La Jolla, California • Los Angeles, California • Newport Beach, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 29, 2026, 10:34 PM EDT
Recruiting Phase 1 Interventional

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT05283330
View directory record Official record
Conditions
Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
Interventions
²¹²Pb-DOTAM-GRPR1
Drug
Lead sponsor
Orano Med Theranostics, SAS
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
8
States / cities
Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 29, 2026, 10:34 PM EDT
Terminated Phase 1Phase 2 Interventional

Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer

NCT00087334
View directory record Official record
Conditions
Colorectal Cancer
Interventions
capecitabine, gefitinib, oxaliplatin
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 29, 2026, 10:34 PM EDT
Terminated Not applicable Interventional

Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases

NCT02866344
View directory record Official record
Conditions
Colorectal Neoplasms, Neoplasm Metastasis, Hepatic Neoplasms
Interventions
Microwave ablation, Hepatic resection
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Oct 29, 2026, 10:34 PM EDT
Terminated No phase listed Observational

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

NCT01096381
View directory record Official record
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 27, 2012 · Synced Oct 29, 2026, 10:34 PM EDT
Completed Phase 2 Interventional

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation

NCT05593328
View directory record Official record
Conditions
Colorectal Cancer, Metastatic Colorectal Cancer
Interventions
Onvansertib, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Cardiff Oncology
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
27
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 29, 2026, 10:34 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer

NCT01086267
View directory record Official record
Conditions
Colorectal Cancer
Interventions
BMS-908662, Cetuximab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Scottsdale, Arizona • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 29, 2026, 10:34 PM EDT
Completed Phase 2 Interventional Results available

Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer

NCT00504153
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
dasatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 29, 2026, 10:34 PM EDT
Completed No phase listed Observational

Study of the Therapeutic Use of Language in Patients With Metastatic Colorectal Cancer

NCT00711672
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Hematology and Oncology Associates of NE Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dunmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 29, 2026, 10:34 PM EDT
Terminated Phase 2 Interventional Results available

Maintenance Dovitinib for Colorectal and Pancreas Cancer

NCT01888965
View directory record Official record
Conditions
Colorectal Cancer, Pancreas Cancer
Interventions
Dovitinib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 29, 2026, 10:34 PM EDT